News | January 07, 2026
Merck completes acquisition of Cidara Therapeutics
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Subscribe To Our Newsletter & Stay Updated
